About Us

"RhoVac conducts research and
development on therapeutic
cancer vaccines."

RhoVac

Operations

RhoVac is a biotechnology company conducting research and development in immunotherapy, more specifically – on therapeutic cancer vaccines. The company’s primary focus is to develop a drug with the potential to prevent or limit metastases in metastatic cancers.

Group Relationships and Shareholdings

The RhoVac Group comprises parent company RhoVac AB and the wholly-owned subsidiary RhoVac ApS. All operations are conducted through the subsidiary. RhoVac AB’s only business activity is ownership of the RhoVac ApS subsidiary. RhoVac has no shareholdings in any companies other than the above.

Business model

RhoVac intends to license or sell all, or part of, operations as soon as possible after Clinical Phase I/II Studies have been completed. The Board continually evaluates how best to create value in the company, concentrating on generating value by licensing or selling operations.

History

A brief overview of RhoVac’s history is presented below. RhoVac ApS was established in 2007. RhoVac AB, the group parent company, was established November 2015.

TimelineEvent
2007RhoVac ApS established and commences operations.
2007National patent application submitted.
2008International patent application submitted.
2009RhoVac completes toxicology study (non-GLP) with good results.
2009RhoVac is approved for an Innovation loan from Nordea Fonden (DK).
2012RhoVac receives development funding from the Danish Agency for Science, Technology and Innovation.
2013Patent granted in Australia.
2014RhoVac establishes cooperation with Ventac Partners.
2015Patent granted in Japan.
2015Patent granted in USA.
2015Process development of the pharmaceutical substance and analytical development.
2015RhoVac initiates toxicology study in accordance with GLP.
2015First batch of the pharmaceutical substance is produced and stability studies commence.
2015RhoVac AB established.
2016RhoVac AB Listed on AktieTorget.
2016Report submitted on the clear Toxicology Study.
2016Production of pharmaceutical drug substance and pharmaceutical product concluded.
2016Application for clinical trial submitted.
2016Research collaboration with the University of Tübingen in Germany commenced.
2017Approval granted for start of Clinical Phase I/II Study.
2017Patent granted by the European Patent Office.
2017Second patent granted by the Japanese Patent Office.
2017First patient treated in the Clinical Phase I/II Study

Development Plan

The main milestones in RhoVac’s development of its primary candidate, RV0001, are presented in overview below.

2017

  • Complete patient recruitment to ongoing Clinical Phase I/II Study
  • Treatment of all patients in the Clinical Phase I/II Study
  • Definition of the Clinical Phase IIb programme

2018

  • Completion of treatment for all patients in the Clinical Phase I/II Study
  • Summary and Final Report of the Clinical Phase I/II Study (Q2)